0001572426-15-000106.txt : 20150820
0001572426-15-000106.hdr.sgml : 20150820
20150820191556
ACCESSION NUMBER: 0001572426-15-000106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150820
FILED AS OF DATE: 20150820
DATE AS OF CHANGE: 20150820
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: NATL INST FOR BIOPROCESSING RESEARCH
STREET 2: FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK CO. DUBLIN
STATE: L2
ZIP: 00000
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: NATL INST FOR BIOPROCESSING RESEARCH
STREET 2: FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK CO. DUBLIN
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heffernan Mark
CENTRAL INDEX KEY: 0001632439
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 151067325
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-08-20
0001618561
Nexvet Biopharma plc
NVET
0001632439
Heffernan Mark
C/O NEXVET BIOPHARMA PLC
NIBRT, FOSTERS AVENUE, MOUNT MERRION
BLACKROCK
L2
IRELAND
1
1
0
0
Chief Executive Officer
Ordinary Shares
2015-08-20
4
A
0
4834
.125
A
12084
D
Ordinary Shares
234383
I
By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>
Option to Purchase Shares
.125
2015-08-20
4
M
0
4834
0
D
2015-07-01
2019-07-01
Ordinary Shares
4834
16916
D
The reporting person and his spouse share voting and dispositive power with respect to the reported securities.
The option to purchase 4,834 shares vested on 7/1/15 and was exercised on 8/20/15; the option to purchase 4,833 shares will vest and become exercisable on each of 7/1/16 and 7/1/17. The option to purchase the remaining 7,250 shares will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors; such completion must occur on or before 7/1/19.
/s/ Mark Heffernan by Geraldine Farrell, Attorney-in-Fact
2015-08-20